Literature DB >> 2297455

Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.

Y Horai1, J Taga, T Ishizaki, K Ishikawa.   

Abstract

The study was aimed at defining the relationships among the oxidative capacities for three prototype drugs, metoprolol, debrisoquine and sparteine, used for assessing genetically determined polymorphism of drug oxidation in a Japanese population. Among 292 unrelated healthy Japanese subjects who had been defined as extensive (EMs, n = 291) or poor (PM, n = 1) metabolisers of metoprolol oxidation, 55 subjects (EMs = 54 and PM = 1) were selected. One PM of metoprolol oxidation was also identified as a PM not only of debrisoquine but also of sparteine, and no misclassification by the three phenotypic methods was observed. All three correlations among the metabolic ratios of the three test probes assessed by Spearman's rank test were highly significant (P less than 0.001). These findings indicate that in Japanese subjects the oxidation capacities of metoprolol, debrisoquine, and sparteine are closely related. It appears that in Japanese the polymorphic oxidation of the three drugs is co-regulated, either by the same enzyme or gene-controlling system.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2297455      PMCID: PMC1380068          DOI: 10.1111/j.1365-2125.1990.tb03609.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  The genetic polymorphism of sparteine metabolism.

Authors:  M Eichelbaum; K P Reetz; E K Schmidt; C Zekorn
Journal:  Xenobiotica       Date:  1986-05       Impact factor: 1.908

2.  Determination of debrisoquine and its 4-hydroxy metabolite in urine by high-performance liquid chromatography.

Authors:  P M Harrison; A M Tonkin; S T Dixon; A J McLean
Journal:  J Chromatogr       Date:  1986-01-10

3.  Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians.

Authors:  N M Woolhouse; M Eichelbaum; N S Oates; J R Idle; R L Smith
Journal:  Clin Pharmacol Ther       Date:  1985-05       Impact factor: 6.875

4.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.

Authors:  K Nakamura; F Goto; W A Ray; C B McAllister; E Jacqz; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

5.  Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

Authors:  M Eichelbaum; L Bertilsson; J Säwe; C Zekorn
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

6.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

7.  Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.

Authors:  J C McGourty; J H Silas; M S Lennard; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

8.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

9.  The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.

Authors:  D A Evans; D Harmer; D Y Downham; E J Whibley; J R Idle; J Ritchie; R L Smith
Journal:  J Med Genet       Date:  1983-10       Impact factor: 6.318

10.  Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation.

Authors:  A O Iyun; M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacol Ther       Date:  1986-10       Impact factor: 6.875

View more
  6 in total

1.  Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.

Authors:  S L Bramer; A Suri
Journal:  Clin Pharmacokinet       Date:  1999       Impact factor: 6.447

2.  Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study.

Authors:  A Bozkurt; N E Basçi; A Işimer; A Sayal; S O Kayaalp
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Oct-Dec       Impact factor: 2.441

3.  The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.

Authors:  T Ebner; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

4.  S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population.

Authors:  N E Basci; K Brosen; A Bozkurt; A Isimer; A Sayal; S O Kayaalp
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

Review 5.  Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.

Authors:  L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1995-09       Impact factor: 6.447

Review 6.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.